- Home
- CDNA vs BRSP Comparison
CDNA vs BRSP Comparison
Compare CDNA & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- BRSP
- Stock Information
- Founded
- CDNA 1998
- BRSP 2017
- Country
- CDNA United States
- BRSP United States
- Employees
- CDNA N/A
- BRSP N/A
- Industry
- CDNA Medical Specialities
- BRSP Real Estate Investment Trusts
- Sector
- CDNA Health Care
- BRSP Real Estate
- Exchange
- CDNA Nasdaq
- BRSP Nasdaq
- Market Cap
- CDNA 712.2M
- BRSP 683.8M
- IPO Year
- CDNA 2014
- BRSP 2018
- Fundamental
- Price
- CDNA $14.50
- BRSP $5.25
- Analyst Decision
- CDNA Buy
- BRSP Buy
- Analyst Count
- CDNA 8
- BRSP 3
- Target Price
- CDNA $26.86
- BRSP $6.00
- AVG Volume (30 Days)
- CDNA 951.2K
- BRSP 588.5K
- Earning Date
- CDNA 11-04-2025
- BRSP 10-28-2025
- Dividend Yield
- CDNA N/A
- BRSP 12.38%
- EPS Growth
- CDNA N/A
- BRSP N/A
- EPS
- CDNA 1.00
- BRSP N/A
- Revenue
- CDNA $340,826,000.00
- BRSP $330,894,000.00
- Revenue This Year
- CDNA $12.73
- BRSP N/A
- Revenue Next Year
- CDNA $11.90
- BRSP $0.74
- P/E Ratio
- CDNA $14.81
- BRSP N/A
- Revenue Growth
- CDNA 14.72
- BRSP N/A
- 52 Week Low
- CDNA $10.96
- BRSP $4.16
- 52 Week High
- CDNA $26.37
- BRSP $6.45
- Technical
- Relative Strength Index (RSI)
- CDNA 48.78
- BRSP 44.90
- Support Level
- CDNA $14.23
- BRSP $5.28
- Resistance Level
- CDNA $15.29
- BRSP $5.47
- Average True Range (ATR)
- CDNA 0.63
- BRSP 0.11
- MACD
- CDNA -0.05
- BRSP 0.01
- Stochastic Oscillator
- CDNA 31.72
- BRSP 33.82
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.